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Background. Staphylococcus aureus (S. aureus) is a major pathogen responsible for mastitis in dairy herds. The 
multidrug resistance and/or formation of S. aureus biofilm, considered as a one of the virulent factor, may 
explain why mastitis is difficult to treat and persists in herd as chronic or recurrent disease. These factors often 
results in the frequent failure of antibiotic therapy and economic lost in dairy industry [1]. In this context, the 
development of new strategies, as alternatives or complements to antibiotic therapy for the management of 
mastitis, is particularly appealing. One sustainable alternative to treat or prevent mastitis with avoiding intra-
mammary biofilm formation is the use of lactic acid bacteria (LAB) or their extracellular metabolites as 
mammary probiotics.  
Methods. In present in vitro study, we evaluated the ability of CFCSs (Cell Free Culture Supernatants) from two 
ovine Lactobacillus mucosae (L. mucosae) isolates to prevent S. aureus (three ovine isolates from acute mastitis) 
biofilm formation using by molecular approaches as Fluorescence in situ Hybridization (FISH) and Flow 
Cytometry method combined with 16S rRNA fluorescent labelled probes (FISH-FCM) as well as 
spectrophotometric crystal violet assay (SCVA).  
Results. The strongest biofilm forming ability determined was shown by S. aureus 91 (FISH: 8,37±0,19; FISH-
FCM: 8,35±0,11, both given as log10 of biofilm forming bacteria numbers per well ± SD (standard deviation); 
SCVA: 0,524±0,13, given as average values of absorbance measurement  in 570 nm (A570 ± SD) in 
comparison with other two isolates 20 (FISH: 8,26±0,07; FISH-FCM: 8,32±0,03; SCVA: 0,381±0,03) and 203 
(FISH: 8,21±0,10; FISH-FCM: 8,20±0,13; SCVA: 0,479±0,06). The CFCSs of L. mucosae strains affected S.
aureus biofilm formation in a strain-dependent manner. The most significant anti-biofilm effect was caused by L.
mucosae 14K CFCS on S. aureus 203 (percentages of S. aureus biofilm formation after treatment ranged from 
1,74 to 3,76%, detected by three methods). L. mucosae OV6 mediated approximately 10-fold diminishing of S.
aureus biofilm formation, with exception of S. aureus 203 with higher discrepancy results achieved by FISH 
method and S. aureus 20 in results obtained by SCVA. Pearson´s R correlation test showed positive correlation 
of used methods with correlation coefficient (r) ranging within 0,719 - 0,923 and probability p<0,0001. 
Conclusions. The ovine L. mucosae 14K CFCS appears to be an efficient alternative to the use of commonly 
prescribed antibiotics for the prevention of S.aureus biofilm formation, which may be responsible for troubles in 
treatment of infection mastitis. Antimicrobial metabolites from CFCS of L.mucosae 14K were effective in 
repressing the S. aureus biofilm. The future of our study will be concentrated on determination of antimicrobial 
compounds types secreted by L. mucosae 14K although seeing that, the L. mucosae isolates CFCS inhibited S.
aureus biofilm formation without affecting bacteria growth, thus, the way in which these extracellular products 
influence bacterial-surface interaction seems to be more closely related to changes in surface tension and 
bacterial cell-wall charge.
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Today, we are facing a major challenge regarding the development of new strategies and the discovery of new 
compounds with effective antimicrobial outcomes. The emergence of resistance is a preoccupant health threat 
and conventional antibiotics are being rendered ineffective [1]. Specifically, biofilm related infections are 
becoming a serious threat, being highly related to chronic infections but also nosocomial and biomaterial related 
infections, and they are considered the major cause of dissemination of antibiotic resistance in the nosocomial 
scenario [2]. 
Researchers are now focusing in alternatives, such as the discovery of new antimicrobials with different modes 
of action, and the combination of agents potentiating their efficacy. AMPs are an example of new antimicrobials 
with promising applications, since they have different and sometimes unspecific mechanisms of action compared 
to traditional antibiotics, reducing the chance of acquired resistance, and are showing promising results in the 
biofilm area [3]. 
A growing interest has been emerging for the use of antimicrobial combinations as a strategy to increase the 
antimicrobial spectrum, prevent the emergence of resistance, reduce toxicity and side effects and provide 
synergistic activity. Because of this, in this work we analyse AMP combinations against major pathogenic 
bacteria, Pseudomonas aeruginosa and Staphylococcus aureus, currently great contributors for resistance 
development and responsible for chronic infections, such as cystic fibrosis pneumonia.  
We present a screening of combinations of the AMP antibiotic colistin with the AMPs temporin A, citropin 1.1 
and tachyplesin I against these pathogens, including references and clinical isolated strains. Planktonic and 
biofilm mode of growth were implemented and results show that most combinations have addictive and 
synergetic activities, including total inhibition of biofilm formation for some of the combinations tested. This 
means that AMP combinations should be a viable way for the development of new antimicrobial treatments, thus 
reducing their toxicity and side effects, while maintaining efficacy. 
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